New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Adding tumor-bed biopsy to trimodality imaging after neoadjuvant chemotherapy did not reliably predict pathological complete ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

Researchers found people given a shingles vaccine had a 23% lower risk of cardiovascular events, including stroke, heart ...

Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...